Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, publishes PCT application.

New York, May 26, 2023 /PRNewswire/ — Terran Biosciences (“Terran”), a biotech platform company dedicated to the development of transformational therapeutics for neurological and psychiatric diseases, has announced the publication of a PCT patent application covering what may be the first comprehensive salt and polymorph screens of the empathogens MDMA, (R)-MDMA, (S)-MDMA, MDEA (MDE), (S)-MDEA…

Source